NextFin News - China's biotech stocks have staged a 60% rally since January that is handily outpacing the country's AI-fueled technology surge, and after a week of sharp swings in tech shares, investors are rotating into healthcare as a defensive play on undervalued fundamentals.
The move is drawing fresh commentary from sell-side strategists. In a television interview, Bernstein's Liang weighed in on what is driving the sector's rebound: deep valuation discounts after a four-year selloff, a wave of billion-dollar licensing deals that validate Chinese drug innovation, and policy support from Beijing aimed at opening the pharmaceutical sector to foreign capital.
The Hang Seng Biotech Index has climbed more than 60% since the start of the year, beating the 17% gain in China's technology stocks that followed the January release of DeepSeek's breakthrough artificial-intelligence application. The contrast matters. The AI rally was built on expectations about future computing demand; the biotech move is being underwritten by signed contracts and cash upfront.
The Rally Has Real Deals Behind It
The clearest evidence that this is more than a liquidity bounce is the deal flow. Pfizer said on May 19 that it had agreed to pay US$1.25 billion to license an experimental cancer drug from China's 3SBio and to invest a further US$100 million in the company's shares. Weeks later, Bristol-Myers Squibb signed a deal worth up to US$11.5 billion for a cancer therapy that Germany's BioNTech had originally licensed from China's Biotheus. Novo Nordisk agreed to license a weight-loss treatment from Hengrui Pharma in a transaction that could reach US$2.6 billion, including US$300 million upfront. Eli Lilly added a research-and-development partnership with Chinese biotech Abbisko valued at as much as US$1.9 billion.
Those transactions are not marginal. Mergers and acquisitions involving Chinese biotech firms reached US$36.9 billion in the first quarter alone, more than half of global biotech deal totals, according to deal-tracking data. The market is responding stock by stock: 3SBio shares have soared 283% this year, while RemeGen has gained 270% as of June. Duality Biotherapeutics more than doubled on its first trading day in April and has since added 189%. Jiangsu Hengrui, China's largest drugmaker by market value, rose 25% on its May debut.
"China's innovative drug pipeline is advancing at a global leading speed and cost," said analysts at Citi in a research note, adding that they see "high management confidence and strong operational momentum across the value chain."
The pipeline of new listings confirms the momentum. Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the final two days of September, including online healthcare services provider We Doctor Holdings, cancer-drug developer Betta Pharmaceuticals, and Sichuan Biokin Pharmaceutical, known for a US$8.4 billion licensing arrangement with Bristol-Myers Squibb. We Doctor's first-half revenue jumped 69% year over year to 3.08 billion yuan, or US$433 million, according to its prospectus.
Why Investors Are Rotating Into Healthcare Now
The immediate trigger for this week's gains was a classic flight to safety. Sharp swings in technology stocks prompted some traders to move into healthcare, a heavily sold sector with strong fundamentals, said Jialin Zhang, a China healthcare analyst at Nomura. The rotation logic is straightforward: after a multi-year drawdown, Chinese healthcare stocks were cheap, crowded positioning was light, and the sector offered earnings visibility that volatile technology names could not.
Policy support arrived at the same time. Measures jointly issued by China's commerce and finance ministries and the National Development and Reform Commission to encourage foreign investment in the pharmaceutical sector include broader commercial insurance coverage for innovative drugs and expanded retail sales channels for foreign medicines. The announcements signal continued commitment from Chinese authorities to opening the sector to foreign capital, analysts said.
WuXi-named companies led the healthcare sector higher. WuXi AppTec's Hong Kong-listed shares rose as much as 11% before closing 8.3% higher, while its Shanghai-listed stock gained as much as 10% to finish 8.6% up. WuXi Biologics added 8.9% and WuXi XDC rose 4.2%. Peers BeOne Medicines and Innovent Biologics advanced 2.7% and 1.5%, respectively, in Hong Kong. Citi attributed part of the outperformance to recent share-buyback plans that reflect management confidence in the underlying businesses.
The Second-Order Effect: A Re-Rating That Spreads Beyond China
The first-order read of this rally is simple: Chinese biotech stocks were cheap, and now they are less cheap. The second-order effect is what matters more, and the market has not fully priced it. As Chinese biotechs transition from domestic cash-flow stories to global royalty streams, the re-rating transmits across three channels.
First, the discount rate channel. Western pharma buying Chinese assets at a fraction of Western R&D cost forces a downward revision in the cost of innovation for the entire global industry. A drug candidate that costs a third as much to develop in China and can be licensed for ex-China rights lowers the expected capital required per approved molecule. That compresses the risk premium investors demand from all biotech developers, not just Chinese ones.
Second, the M&A channel. The US$36.9 billion first-quarter total - more than half of global biotech deal value - is not a one-off reallocation. It is a structural response to the patent cliff facing the world's largest drugmakers. As long as blockbuster revenues remain exposed to loss of exclusivity and internal pipelines remain thin, Western pharma will keep returning to China as a repeat buyer. Each completed deal raises the reference price for the next one, creating a self-reinforcing floor under Chinese asset valuations.
Third, the expectation-gap channel. The market has priced Chinese biotech as a domestic-play sector with a geopolitical discount. The licensing wave says otherwise: these companies are already embedded in Western pharmaceutical supply chains as innovation partners rather than exporters, which limits tariff exposure and makes the discount increasingly hard to justify. The gap between the priced-in narrative and the contractual reality is where the remaining upside sits.
This is the mechanism that separates the biotech rally from the AI rally. A technology surge built on inference-cost expectations can reverse on a single benchmark result. A licensing deal with upfront cash and defined milestones cannot be un-signed. The contracts themselves become the transmission belt, carrying the re-rating from Hong Kong-listed developers into the earnings models of Western licensees.
The Structural Shift: From Copycats to Originators
Beneath the daily moves lies a deeper change. For two decades, China's pharmaceutical industry was a low-margin supplier of generic ingredients and contract manufacturing. The licensing wave marks a regime shift: Chinese firms are now originating novel drug candidates that Western pharmaceutical giants are willing to pay billions to commercialize outside China.
The mechanism is economic, not patriotic. Western drugmakers face patent cliffs on their biggest products and need external innovation to refill pipelines. Chinese biotechs can run clinical programs faster and at lower cost, supported by a favorable policy environment and a large, treatment-hungry domestic patient population. The result is an arbitrage: assets priced on China-only cash flows are being revalued as global royalty streams once a Western partner buys ex-China rights.
"Chinese biotech is having its own DeepSeek moment," said Dong Chen, chief Asia strategist at Pictet Wealth Management, drawing a parallel to the artificial-intelligence boom that drove Chinese technology stocks earlier in the year. The comparison is apt in one respect and dangerous in another. Like DeepSeek, Chinese biotech has demonstrated that it can produce world-class output at a fraction of Western cost. Unlike an AI model, a licensed drug candidate carries contractual milestone payments and royalties that are visible on a balance sheet.
The Cyclical Overlay: Why This Rally Can Overreach
But not all of the 60% move is structural. A significant portion is cyclical and mean-reverting, and the distinction matters because the two forces call for opposite positioning. The sector entered 2026 after a four-year slump that left valuations depressed and positioning light. The "fly to safety" rotation is, by definition, a short-term flow dynamic: money moves out of technology and into healthcare because tech is volatile, not because healthcare fundamentals changed overnight.
History offers three comparable cycles. The 2018-2019 biotech rebound followed the first wave of Hong Kong listings for pre-revenue companies and faded as the US-China trade dispute tightened financing. The 2020-2021 surge rode the pandemic innovation wave and reversed when global liquidity turned in 2022. The current rally shares the valuation setup of both but differs in the catalyst: this time the upside is anchored by signed licensing contracts rather than by multiple expansion alone. That difference is why the cyclical leg can extend further than the previous two, but it remains a leg, not the whole journey.
Policy catalysts are also cyclical in effect. Insurance-coverage expansions and retail-channel reforms improve the investment case, but they do not by themselves create new drugs. They raise the multiple investors are willing to pay for existing pipelines. When the multiple expansion is done, further returns must come from earnings growth, and that is where the dispersion between winners and losers will widen.
The concentration risk is real. The headline deal values are dominated by a small number of transactions and a small number of companies. 3SBio and RemeGen account for a disproportionate share of the index's gains. Investors chasing the index are implicitly betting that the licensing model will diffuse across the broader universe of Chinese biotechs, and that diffusion is not guaranteed. Many smaller developers still burn cash with no approved product and no partner.
The Counter-Thesis: This Is a Liquidity Rally, Not a Re-Rating
The strongest case against the structural interpretation is that this is a liquidity-driven policy rally in a sector with weak cash flows. The bear argument runs as follows: Chinese biotechs remain dependent on external financing; the licensing deals are concentrated in a handful of oncology assets; the "fly to safety" rotation will reverse as soon as technology stocks stabilize; and geopolitical friction could re-impose the valuation discount at any time. Under this view, the 60% rally is a bear-market rebound, not a regime change, and mean reversion will pull the index back toward its long-run discount to global peers.
There is merit in the caution. A licensing deal is only as good as the underlying clinical data, and late-stage failures can erase billions of paper value quickly. The US$11.5 billion Bristol-Myers deal, the largest on the board, is heavily weighted toward contingent milestones that may never be paid. And the policy support that lifted sentiment this week can be withdrawn or redirected as quickly as it was announced.
Yet the bear case misses the direction of travel. Even if individual deals disappoint, the structural vector is clear: Western pharma is now a repeat buyer of Chinese innovation, not an occasional visitor. Pfizer, Bristol-Myers Squibb, Novo Nordisk, and Eli Lilly have all committed capital in a short window. That is a pattern, not an anomaly. The question is not whether the pattern exists; it is how much of it is already priced.
What Would Prove the Bull Case Wrong
The structural re-rating thesis has a clear falsifying signal. If the Hang Seng Biotech Index gives back more than half of its year-to-date advance - falling back below roughly a 30% year-to-date gain - within the next two quarters, the re-rating narrative is broken. Equivalently, if outbound licensing deal value involving Chinese biotech firms drops below the prior-year pace for two consecutive quarters, the "China as a net exporter of drug innovation" thesis fails. Either outcome would confirm that the rally was cyclical liquidity, not structural change.
What to Watch: Three Time Horizons
Short term (sentiment and flows): The sector's direction depends on whether the flight-to-safety rotation persists. Watch technology-stock volatility as the inverse signal: if tech stabilizes, defensive buying in healthcare could fade. The policy measures announced this week are the near-term catalyst, and any follow-through from Beijing on insurance coverage or foreign-investment rules would extend the rally.
Medium term (fundamentals): The next earnings season will separate companies with real licensing revenue from those trading on expectations. Watch for upfront payments hitting the cash-flow statement, milestone achievements, and clinical data readouts from the most heavily owned names. Companies that can show contracted revenue, not just pipeline value, will hold their gains.
Long term (structural): The regime-shift argument rests on two durable factors: the return of Western-trained scientific talent to China, and the continued willingness of Western pharmaceutical companies to source innovation there. Geopolitical friction is the main threat to both. Many Chinese biotechs already operate as partners to U.S. drugmakers rather than as direct exporters, which may limit tariff exposure, but policy risk cannot be diversified away.
Scenarios
Base case: The Hang Seng Biotech Index consolidates its year-to-date gains, with further upside driven by additional licensing announcements and a steady IPO pipeline. Dispersion widens between companies with partnered assets and those without. The sector remains a structural overweight for investors seeking China exposure outside technology.
Upside case: A new wave of mega-deals - transactions above US$5 billion - validates the re-rating, pulling more global capital into the sector. The index extends its advance as Chinese biotechs transition from licensing fees to commercial royalties.
Downside case: Technology stocks stabilize, the defensive rotation unwinds, and a high-profile clinical failure triggers a broader de-rating. Licensing activity slows on geopolitical concerns, and the index retraces toward its historical discount to global healthcare peers.
The rally in China's biotech stocks is part liquidity, part policy, and part genuine structural change - and investors who treat all three as the same thing will mistake a rotation for a revolution, or a revolution for a rotation. The deals are real. The discount was real. The question now is which companies can turn licensed potential into earned revenue, because that is the only metric that will survive the next cycle.
更多独家洞察尽在 nextfin.ai.
